A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 06 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.
- 06 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 14 Jun 2016 Status changed from not yet recruiting to recruiting.